Adam Sperling, MD, PhD
@adamssperling.bsky.social
Physician scientist UCLA --> BWH <--> DFCI. Myeloma, CAR-T, CHIP, MDS. LA sports fan stuck in Boston.
Reposted by Adam Sperling, MD, PhD
@paralkarlab.bsky.social
Hello, since you are a hematology/oncology influencer, could you re-post my thing about the Myeloid Workshop being on despite ASH not getting it up on the website? Thank you!
Hello, since you are a hematology/oncology influencer, could you re-post my thing about the Myeloid Workshop being on despite ASH not getting it up on the website? Thank you!
November 4, 2025 at 11:43 PM
@paralkarlab.bsky.social
Hello, since you are a hematology/oncology influencer, could you re-post my thing about the Myeloid Workshop being on despite ASH not getting it up on the website? Thank you!
Hello, since you are a hematology/oncology influencer, could you re-post my thing about the Myeloid Workshop being on despite ASH not getting it up on the website? Thank you!
Congrats to Yu-Hsiang Chen, Pavan Bachireddy, and team at @mdanderson.bsky.social for getting this important work out. By understanding how MRD cells escape therapy at a more basic level hopefully we can eventually cure more patients with MDS. www.biorxiv.org/content/10.1...
Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromes
Cancer relapse after treatment invariably proceeds from the persistence and progression of measurable residual disease (MRD), an ultrasmall malignant population. Despite the poor prognostic impact est...
www.biorxiv.org
October 20, 2025 at 1:43 PM
Congrats to Yu-Hsiang Chen, Pavan Bachireddy, and team at @mdanderson.bsky.social for getting this important work out. By understanding how MRD cells escape therapy at a more basic level hopefully we can eventually cure more patients with MDS. www.biorxiv.org/content/10.1...
Reposted by Adam Sperling, MD, PhD
Journalist here
I’m interested in talking to a federal agency scientist who was fired, then rehired. I can keep you anonymous. I’m on Signal ginnyg.04
Reposts are appreciated!
I’m interested in talking to a federal agency scientist who was fired, then rehired. I can keep you anonymous. I’m on Signal ginnyg.04
Reposts are appreciated!
October 11, 2025 at 12:22 AM
Journalist here
I’m interested in talking to a federal agency scientist who was fired, then rehired. I can keep you anonymous. I’m on Signal ginnyg.04
Reposts are appreciated!
I’m interested in talking to a federal agency scientist who was fired, then rehired. I can keep you anonymous. I’m on Signal ginnyg.04
Reposts are appreciated!
Reposted by Adam Sperling, MD, PhD
Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration.
Learn more: bit.ly/4pRWiZy
Learn more: bit.ly/4pRWiZy
September 29, 2025 at 9:05 PM
Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration.
Learn more: bit.ly/4pRWiZy
Learn more: bit.ly/4pRWiZy
Reposted by Adam Sperling, MD, PhD
Epigenetic diagnosis of acute leukemia within two hours from sample receipt 🚀
Very happy to share the results of a great collaboration between @hovestadt.bsky.social and Griffin Labs, I co-led with @sbenfatto.bsky.social, published today in @natgenet.nature.com
📄 www.nature.com/articles/s41...
🧵1/n
Very happy to share the results of a great collaboration between @hovestadt.bsky.social and Griffin Labs, I co-led with @sbenfatto.bsky.social, published today in @natgenet.nature.com
📄 www.nature.com/articles/s41...
🧵1/n
Rapid epigenomic classification of acute leukemia - Nature Genetics
The authors present a molecular classification of acute leukemia using 5-methylcytosine signatures, together with a neural network-based classifier for clinical use.
www.nature.com
September 22, 2025 at 8:41 PM
Epigenetic diagnosis of acute leukemia within two hours from sample receipt 🚀
Very happy to share the results of a great collaboration between @hovestadt.bsky.social and Griffin Labs, I co-led with @sbenfatto.bsky.social, published today in @natgenet.nature.com
📄 www.nature.com/articles/s41...
🧵1/n
Very happy to share the results of a great collaboration between @hovestadt.bsky.social and Griffin Labs, I co-led with @sbenfatto.bsky.social, published today in @natgenet.nature.com
📄 www.nature.com/articles/s41...
🧵1/n
Dr. Rashidian from @danafarbernews.bsky.social presenting his work at the 2025 @myeloma-society.bsky.social meeting.
September 19, 2025 at 7:37 PM
Dr. Rashidian from @danafarbernews.bsky.social presenting his work at the 2025 @myeloma-society.bsky.social meeting.
Reposted by Adam Sperling, MD, PhD
Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology.
Learn more: bit.ly/45wiiQ6
Learn more: bit.ly/45wiiQ6
Alice T. Shaw named Chair of Department of Medical Oncology at Dana-Farber Cancer Institute | Dana-Farber Cancer Institute
Alice T. Shaw, MD, PhD, was named Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute, in an announcement today.
bit.ly
August 12, 2025 at 1:45 PM
Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology.
Learn more: bit.ly/45wiiQ6
Learn more: bit.ly/45wiiQ6
Reposted by Adam Sperling, MD, PhD
The Myeloid Workshop is back in ASH! Please contact the organizers if you have an exciting story that will not be out by December they are: Zuzana Tothova ,
@ernstlaboratory.bsky.social
@steidluli.bsky.social
@ericpietras.bsky.social
@kathrinbernt.bsky.social
@gritsmanlab.bsky.social
@ernstlaboratory.bsky.social
@steidluli.bsky.social
@ericpietras.bsky.social
@kathrinbernt.bsky.social
@gritsmanlab.bsky.social
July 21, 2025 at 7:27 PM
The Myeloid Workshop is back in ASH! Please contact the organizers if you have an exciting story that will not be out by December they are: Zuzana Tothova ,
@ernstlaboratory.bsky.social
@steidluli.bsky.social
@ericpietras.bsky.social
@kathrinbernt.bsky.social
@gritsmanlab.bsky.social
@ernstlaboratory.bsky.social
@steidluli.bsky.social
@ericpietras.bsky.social
@kathrinbernt.bsky.social
@gritsmanlab.bsky.social
Super interesting. Congrats on getting this out.
And here it is! Our study in clonal hematopoiesis and Alzheimer’s disease — product of 5 years’ gestation. urldefense.proofpoint.com/v2/url?u=htt...
ScienceDirect.com | Science, health and medical journals, full text articles and books.
urldefense.proofpoint.com
July 2, 2025 at 5:34 PM
Super interesting. Congrats on getting this out.
Reposted by Adam Sperling, MD, PhD
And here it is! Our study in clonal hematopoiesis and Alzheimer’s disease — product of 5 years’ gestation. urldefense.proofpoint.com/v2/url?u=htt...
ScienceDirect.com | Science, health and medical journals, full text articles and books.
urldefense.proofpoint.com
July 2, 2025 at 3:17 PM
And here it is! Our study in clonal hematopoiesis and Alzheimer’s disease — product of 5 years’ gestation. urldefense.proofpoint.com/v2/url?u=htt...
Reposted by Adam Sperling, MD, PhD
Major Regulatory Milestone in MM: In response to an application by I2TEAMM and IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @vincentrk.bsky.social
June 26, 2025 at 4:09 AM
Major Regulatory Milestone in MM: In response to an application by I2TEAMM and IMFmyeloma, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! @vincentrk.bsky.social
Reposted by Adam Sperling, MD, PhD
We are proud to announce that the International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma has been published by the Journal of Clinical Oncology! ascopubs.org/doi/10.1200/...
June 10, 2025 at 1:42 PM
We are proud to announce that the International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma has been published by the Journal of Clinical Oncology! ascopubs.org/doi/10.1200/...
Reposted by Adam Sperling, MD, PhD
As someone directly affected by this, let me be clear:
I'd rather lose my job because Harvard chose to fight than keep my job and see a generation of white supremacists parade its corpse around like a war trophy.
I'd rather lose my job because Harvard chose to fight than keep my job and see a generation of white supremacists parade its corpse around like a war trophy.
Researchers at Harvard and its affiliates appreciate that the university resisted the Trump Administration's demands, but worry about what happens next.
At Harvard, scientists worry over the consequences of resisting the Trump administration: $2.2B in grants frozen
Researchers at Harvard and its affiliates appreciate that the university resisted the Trump Administration's demands, but worry about what happens next.
buff.ly
April 15, 2025 at 4:29 PM
As someone directly affected by this, let me be clear:
I'd rather lose my job because Harvard chose to fight than keep my job and see a generation of white supremacists parade its corpse around like a war trophy.
I'd rather lose my job because Harvard chose to fight than keep my job and see a generation of white supremacists parade its corpse around like a war trophy.
Reposted by Adam Sperling, MD, PhD
Meet Yuxin Liu, MD, who treats patients with multiple myeloma and other plasma cell disorders. Her clinical research focuses on novel therapies in newly diagnosed and relapsed multiple myeloma. https://bit.ly/3FljInk
April 3, 2025 at 9:45 PM
Meet Yuxin Liu, MD, who treats patients with multiple myeloma and other plasma cell disorders. Her clinical research focuses on novel therapies in newly diagnosed and relapsed multiple myeloma. https://bit.ly/3FljInk
Reposted by Adam Sperling, MD, PhD
Diet plays a pivotal role in cancer care, yet clear guidelines remain scarce. Dr. Urvi A. Shah explores the evidence, challenges, and need for more robust dietary intervention trials in oncology. ascopost.com/news/march-2...
#OncologyResearch #CancerCare
#OncologyResearch #CancerCare
March 28, 2025 at 3:18 PM
Diet plays a pivotal role in cancer care, yet clear guidelines remain scarce. Dr. Urvi A. Shah explores the evidence, challenges, and need for more robust dietary intervention trials in oncology. ascopost.com/news/march-2...
#OncologyResearch #CancerCare
#OncologyResearch #CancerCare
Multiple myeloma is a terrible disease.
Kevin Drum died on Friday. jabberwocking.com/health-updat...
Health Update - Kevin Drum
With a heavy heart, I have to tell you that after a long battle with cancer my husband Kevin Drum passed away on Friday, March 7, 2025. No public memorial services are planned. In lieu of flowers, ple...
jabberwocking.com
March 10, 2025 at 7:54 PM
Multiple myeloma is a terrible disease.
Reposted by Adam Sperling, MD, PhD
Great news today that my friend and colleague, Dr. Elisabeth Battinelli, has been named chief of classical hematology for Mass General Brigham! Congratulations Beth!
battinellilab.bwh.harvard.edu
battinellilab.bwh.harvard.edu
February 24, 2025 at 9:20 PM
Great news today that my friend and colleague, Dr. Elisabeth Battinelli, has been named chief of classical hematology for Mass General Brigham! Congratulations Beth!
battinellilab.bwh.harvard.edu
battinellilab.bwh.harvard.edu
Reposted by Adam Sperling, MD, PhD
Kudos to our professional societies for advocating for continued funding for lifesaving research through the NIH. There is a link at the end of the statement to contact your representatives!! 👇
The AACR is deeply concerned that the Administration’s recent actions are threatening NIH and its mission to accelerate progress for patients with cancer and other diseases that afflict millions of Americans. Read our statement: https://buff.ly/4gRXNB8
February 19, 2025 at 12:03 AM
Kudos to our professional societies for advocating for continued funding for lifesaving research through the NIH. There is a link at the end of the statement to contact your representatives!! 👇
Reposted by Adam Sperling, MD, PhD
I feel like we could all use something fun to look forward to right about now!!! 🧪🧪🧪
Abstract submission and registration are open for the FASEB Hematologic Malignancies Conference. This is always the BEST meeting!!! Please RT!
events.faseb.org/event/hemato...
Abstract submission and registration are open for the FASEB Hematologic Malignancies Conference. This is always the BEST meeting!!! Please RT!
events.faseb.org/event/hemato...
February 6, 2025 at 5:38 PM
I feel like we could all use something fun to look forward to right about now!!! 🧪🧪🧪
Abstract submission and registration are open for the FASEB Hematologic Malignancies Conference. This is always the BEST meeting!!! Please RT!
events.faseb.org/event/hemato...
Abstract submission and registration are open for the FASEB Hematologic Malignancies Conference. This is always the BEST meeting!!! Please RT!
events.faseb.org/event/hemato...
Reposted by Adam Sperling, MD, PhD
Reposted by Adam Sperling, MD, PhD
Delighted to share our #hematology review article on mutant calreticulin in #MPN
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social
link.springer.com/article/10.1...
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social
link.springer.com/article/10.1...
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications - Current Hematologic Malignancy Reports
Purpose of Review More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continu...
link.springer.com
January 10, 2025 at 3:29 PM
Delighted to share our #hematology review article on mutant calreticulin in #MPN
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social
link.springer.com/article/10.1...
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social
link.springer.com/article/10.1...
Reposted by Adam Sperling, MD, PhD
Three leaders from our cellular therapy & stem cell transplant program were at the White House this week to discuss cell and gene therapy development. We’re grateful to Drs. Corey Cutler, Eric Smith, and Jose Cancelas for their ongoing work to improve access & outcomes with these therapies.
January 8, 2025 at 11:00 PM
Three leaders from our cellular therapy & stem cell transplant program were at the White House this week to discuss cell and gene therapy development. We’re grateful to Drs. Corey Cutler, Eric Smith, and Jose Cancelas for their ongoing work to improve access & outcomes with these therapies.
Reposted by Adam Sperling, MD, PhD
Our latest work is now available to read on bioRxiv! Very proud of this and its potential implications for patients with acute myeloid leukemia 🩸 🧪 🔬💊 **eIF4A-mediated translation initiation as an AML cell vulnerability that can be co-targeted with BCL-2 inhibition** www.biorxiv.org/content/10.1...
December 23, 2024 at 12:54 PM
Our latest work is now available to read on bioRxiv! Very proud of this and its potential implications for patients with acute myeloid leukemia 🩸 🧪 🔬💊 **eIF4A-mediated translation initiation as an AML cell vulnerability that can be co-targeted with BCL-2 inhibition** www.biorxiv.org/content/10.1...
Reposted by Adam Sperling, MD, PhD
